219 related articles for article (PubMed ID: 25983952)
1. The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS.
Cannata-Andía JB; Carrera F
NDT Plus; 2008 Jan; 1(Suppl 1):i2-i6. PubMed ID: 25983952
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
3. Secondary hyperparathyroidism: review of the disease and its treatment.
de Francisco AL
Clin Ther; 2004 Dec; 26(12):1976-93. PubMed ID: 15823762
[TBL] [Abstract][Full Text] [Related]
4. The need for better control of secondary hyperparathyroidism.
Locatelli F
Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V15-19. PubMed ID: 15284355
[TBL] [Abstract][Full Text] [Related]
5. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study.
Fernández-Martín JL; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Gorriz JL; Rutkowski B; Ferreira A; Bos WJ; Covic A; Rodríguez-García M; Sánchez JE; Rodríguez-Puyol D; Cannata-Andia JB;
Nephrol Dial Transplant; 2015 Sep; 30(9):1542-51. PubMed ID: 25920921
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for secondary hyperparathyroidism.
Cozzolino M; Tomlinson J; Walsh L; Bellasi A
Expert Opin Emerg Drugs; 2015 Jun; 20(2):197-208. PubMed ID: 25702624
[TBL] [Abstract][Full Text] [Related]
7. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
8. Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism.
Sakai M; Tokunaga S; Kawai M; Murai M; Kobayashi M; Kitayama T; Saeki S; Kawata T
PLoS One; 2020; 15(4):e0232428. PubMed ID: 32343734
[TBL] [Abstract][Full Text] [Related]
9. Achieving therapeutic targets in the treatment of secondary hyperparathyroidism.
Cunningham J
Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V9-14. PubMed ID: 15284354
[TBL] [Abstract][Full Text] [Related]
10. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes.
Hörl WH
Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V2-8. PubMed ID: 15284353
[TBL] [Abstract][Full Text] [Related]
11. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
[TBL] [Abstract][Full Text] [Related]
12. Impacts of parathyroidectomy on calcium and phosphorus metabolism disorder, arterial calcification and arterial stiffness in haemodialysis patients.
Gao Z; Li X; Miao J; Lun L
Asian J Surg; 2019 Jan; 42(1):6-10. PubMed ID: 29908897
[TBL] [Abstract][Full Text] [Related]
13. Severe secondary hyperparathyroidism in patients on haemodialysis is associated with a high initial serum parathyroid hormone and beta-CrossLaps level: Results from an incident cohort.
Jean G; Lafage-Proust MH; Souberbielle JC; Lechevallier S; Deleaval P; Lorriaux C; Hurot JM; Mayor B; Mehdi M; Chazot C
PLoS One; 2018; 13(6):e0199140. PubMed ID: 29912988
[TBL] [Abstract][Full Text] [Related]
14. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
de Francisco AL
Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956
[TBL] [Abstract][Full Text] [Related]
15. Secondary hyperparathyroidism and target organs in chronic kidney disease.
Nikodimopoulou M; Liakos S
Hippokratia; 2011 Jan; 15(Suppl 1):33-8. PubMed ID: 21897756
[TBL] [Abstract][Full Text] [Related]
16. Mineral metabolism disturbances in patients with chronic kidney disease.
Kestenbaum B; Belozeroff V
Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
[TBL] [Abstract][Full Text] [Related]
17. A new paradigm for the treatment of secondary hyperparathyroidism.
de Francisco AL; Carrera F
NDT Plus; 2008 Jan; 1(Suppl 1):i24-i28. PubMed ID: 25983953
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of parathyroid gland angiogenesis in chronic kidney disease associated with secondary hyperparathyroidism.
Martins P; Schmitt F; Almeida H; Frazão JM
Nephrol Dial Transplant; 2008 Sep; 23(9):2889-94. PubMed ID: 18398016
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of early treatment with calcimimetics in combination with reduced doses of vitamin d sterols in dialysis patients.
Bushinsky DA; Messa P
NDT Plus; 2008 Jan; 1(Suppl 1):i18-i23. PubMed ID: 25983951
[TBL] [Abstract][Full Text] [Related]
20. Medical management of secondary hyperparathyroidism in chronic renal failure.
Goodman WG
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii2-8. PubMed ID: 12771290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
